BioLineRx Ltd. (NASDAQ:BLRX) Short Interest Up 351.3% in October

BioLineRx Ltd. (NASDAQ:BLRX) was the target of a significant increase in short interest in the month of October. As of October 15th, there was short interest totalling 621,400 shares, an increase of 351.3% from the September 30th total of 137,700 shares. Based on an average trading volume of 285,400 shares, the short-interest ratio is currently 2.2 days.

BioLineRx Stock Performance

BLRX traded up $0.01 on Friday, reaching $0.41. The company had a trading volume of 83,232 shares, compared to its average volume of 344,174. The company has a debt-to-equity ratio of 1.34, a quick ratio of 1.49 and a current ratio of 1.61. The stock has a market cap of $33.05 million, a P/E ratio of -0.53 and a beta of 1.46. The company’s fifty day moving average is $0.59 and its 200 day moving average is $0.65. BioLineRx has a fifty-two week low of $0.39 and a fifty-two week high of $1.93.

BioLineRx (NASDAQ:BLRX) last announced its quarterly earnings results on Thursday, August 15th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.09. The company had revenue of $5.39 million for the quarter, compared to the consensus estimate of $3.93 million. As a group, analysts predict that BioLineRx will post -0.25 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, StockNews.com started coverage on BioLineRx in a research note on Wednesday. They issued a “hold” rating on the stock.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in BioLineRx stock. PVG Asset Management Corp purchased a new position in BioLineRx Ltd. (NASDAQ:BLRX) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 123,580 shares of the biotechnology company’s stock, valued at approximately $70,000. PVG Asset Management Corp owned approximately 0.15% of BioLineRx as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 1.56% of the company’s stock.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.